$ACHV Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACHIEVE LIFE SCIENCES, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ACHIEVE LIFE SCIENCES, INC.. Get notifications about new insider transactions in ACHIEVE LIFE SCIENCES, INC. for free.
Page: < prev 1 2 3 4 5 5 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Aug 23 2016 | OGXI | ONCOGENEX PHARMACE ... | Bencich John | CFO | Buy | M | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
Jun 15 2016 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | M | 0.00 | 5,000 | 0 | 10,000 | |
Jun 15 2016 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Sell | S | 1.03 | 1,437 | 1,473 | 77,416 | 78.9 K to 77.4 K (-1.82 %) |
Jun 15 2016 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Buy | M | 0.00 | 5,000 | 0 | 78,853 | 73.9 K to 78.9 K (+6.77 %) |
Jun 15 2016 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | M | 0.00 | 5,000 | 0 | 10,000 | |
Jun 15 2016 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | M | 0.00 | 9,375 | 0 | 18,750 | |
Jun 15 2016 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Buy | M | 0.00 | 5,000 | 0 | 73,743 | 68.7 K to 73.7 K (+7.27 %) |
Jun 15 2016 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Sell | S | 1.03 | 4,856 | 4,979 | 129,428 | 134.3 K to 129.4 K (-3.62 %) |
Jun 15 2016 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Buy | M | 0.00 | 9,375 | 0 | 134,284 | 124.9 K to 134.3 K (+7.51 %) |
May 27 2016 | OGXI | ONCOGENEX PHARMACE ... | Smith David V | Director | Option Exercise | A | 1.00 | 22,500 | 22,500 | 22,500 | |
May 27 2016 | OGXI | ONCOGENEX PHARMACE ... | PARKER H STEWART | Director | Option Exercise | A | 1.00 | 22,500 | 22,500 | 22,500 | |
May 27 2016 | OGXI | ONCOGENEX PHARMACE ... | MATTINGLY MARTIN A | Director | Option Exercise | A | 1.00 | 22,500 | 22,500 | 22,500 | |
May 27 2016 | OGXI | ONCOGENEX PHARMACE ... | GOLDSTEIN JACK | Director | Option Exercise | A | 1.00 | 31,500 | 31,500 | 31,500 | |
May 27 2016 | OGXI | ONCOGENEX PHARMACE ... | Clendeninn Neil James | Director | Option Exercise | A | 1.00 | 22,500 | 22,500 | 22,500 | |
May 24 2016 | OGXI | ONCOGENEX PHARMACE ... | Smith David V | Director | Option Exercise | M | 0.00 | 2,500 | 0 | 0 | |
May 24 2016 | OGXI | ONCOGENEX PHARMACE ... | Smith David V | Director | Buy | M | 0.00 | 2,500 | 0 | 9,500 | 7 K to 9.5 K (+35.71 %) |
May 24 2016 | OGXI | ONCOGENEX PHARMACE ... | PARKER H STEWART | Director | Option Exercise | M | 0.00 | 2,500 | 0 | 0 | |
May 24 2016 | OGXI | ONCOGENEX PHARMACE ... | PARKER H STEWART | Director | Buy | M | 0.00 | 2,500 | 0 | 12,500 | 10 K to 12.5 K (+25.00 %) |
May 24 2016 | OGXI | ONCOGENEX PHARMACE ... | MATTINGLY MARTIN A | Director | Option Exercise | M | 0.00 | 2,500 | 0 | 0 | |
May 24 2016 | OGXI | ONCOGENEX PHARMACE ... | MATTINGLY MARTIN A | Director | Buy | M | 0.00 | 2,500 | 0 | 10,500 | 8 K to 10.5 K (+31.25 %) |
May 24 2016 | OGXI | ONCOGENEX PHARMACE ... | GOLDSTEIN JACK | Director | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | |
May 24 2016 | OGXI | ONCOGENEX PHARMACE ... | GOLDSTEIN JACK | Director | Buy | M | 0.00 | 5,000 | 0 | 17,500 | 12.5 K to 17.5 K (+40.00 %) |
May 24 2016 | OGXI | ONCOGENEX PHARMACE ... | Clendeninn Neil James | Director | Option Exercise | M | 0.00 | 2,500 | 0 | 0 | |
May 24 2016 | OGXI | ONCOGENEX PHARMACE ... | Clendeninn Neil James | Director | Buy | M | 0.00 | 2,500 | 0 | 22,421 | 19.9 K to 22.4 K (+12.55 %) |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | A | 0.85 | 135,000 | 114,750 | 135,000 | |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | M | 0.00 | 4,688 | 0 | 14,062 | |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | M | 0.00 | 3,125 | 0 | 6,250 | |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | M | 0.00 | 2,500 | 0 | 2,500 | |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | M | 0.00 | 1,875 | 0 | 0 | |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Sell | S | 0.83 | 3,254 | 2,701 | 73,853 | 77.1 K to 73.9 K (-4.22 %) |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Buy | M | 0.00 | 12,188 | 0 | 77,107 | 64.9 K to 77.1 K (+18.77 %) |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | Bencich John | CFO | Option Exercise | A | 0.85 | 112,500 | 95,625 | 112,500 | |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | Bencich John | CFO | Option Exercise | M | 0.00 | 3,125 | 0 | 9,375 | |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | Bencich John | CFO | Sell | S | 0.83 | 834 | 692 | 5,864 | 6.7 K to 5.9 K (-12.45 %) |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | Bencich John | CFO | Buy | M | 0.00 | 3,125 | 0 | 6,698 | 3.6 K to 6.7 K (+87.46 %) |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | A | 0.85 | 135,000 | 114,750 | 135,000 | |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | A | 0.85 | 300,000 | 255,000 | 300,000 | |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | M | 0.00 | 9,375 | 0 | 28,125 | |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | M | 0.00 | 6,250 | 0 | 12,500 | |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | M | 0.00 | 4,688 | 0 | 4,687 | |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | M | 0.00 | 4,687 | 0 | 0 | |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Sell | S | 0.83 | 12,033 | 9,987 | 124,909 | 136.9 K to 124.9 K (-8.79 %) |
Mar 16 2016 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Buy | M | 0.00 | 25,000 | 0 | 136,942 | 111.9 K to 136.9 K (+22.33 %) |
Oct 30 2015 | OGXI | ONCOGENEX PHARMACE ... | Clendeninn Neil James | Director | Option Exercise | M | 2.69 | 5,359 | 14,416 | 0 | |
Oct 30 2015 | OGXI | ONCOGENEX PHARMACE ... | Clendeninn Neil James | Director | Buy | M | 2.69 | 5,359 | 14,416 | 19,921 | 14.6 K to 19.9 K (+36.80 %) |
Aug 20 2015 | OGXI | ONCOGENEX PHARMACE ... | Bencich John | CFO | Option Exercise | M | 0.00 | 5,000 | 0 | 15,000 | |
Aug 20 2015 | OGXI | ONCOGENEX PHARMACE ... | Bencich John | CFO | Sell | S | 2.76 | 1,427 | 3,939 | 3,573 | 5 K to 3.6 K (-28.54 %) |
Aug 20 2015 | OGXI | ONCOGENEX PHARMACE ... | Bencich John | CFO | Buy | M | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
Jun 16 2015 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | M | 0.00 | 5,000 | 0 | 15,000 | |
Jun 16 2015 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Sell | S | 2.69 | 1,408 | 3,788 | 64,919 | 66.3 K to 64.9 K (-2.12 %) |
Jun 16 2015 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Buy | M | 0.00 | 5,000 | 0 | 66,327 | 61.3 K to 66.3 K (+8.15 %) |
Jun 16 2015 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | M | 0.00 | 9,375 | 0 | 28,125 | |
Jun 16 2015 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Sell | S | 2.69 | 4,571 | 12,296 | 111,942 | 116.5 K to 111.9 K (-3.92 %) |
Jun 16 2015 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Buy | M | 0.00 | 9,375 | 0 | 116,513 | 107.1 K to 116.5 K (+8.75 %) |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | PARKER H STEWART | Director | Option Exercise | A | 0.00 | 2,500 | 0 | 2,500 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | PARKER H STEWART | Director | Option Exercise | A | 1.89 | 5,000 | 9,450 | 5,000 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | PARKER H STEWART | Director | Option Exercise | M | 0.00 | 2,500 | 0 | 0 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | PARKER H STEWART | Director | Buy | M | 0.00 | 2,500 | 0 | 10,000 | 7.5 K to 10 K (+33.33 %) |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | MATTINGLY MARTIN A | Director | Option Exercise | A | 0.00 | 2,500 | 0 | 2,500 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | MATTINGLY MARTIN A | Director | Option Exercise | A | 1.89 | 5,000 | 9,450 | 5,000 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | MATTINGLY MARTIN A | Director | Option Exercise | M | 0.00 | 2,500 | 0 | 0 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | MATTINGLY MARTIN A | Director | Buy | M | 0.00 | 2,500 | 0 | 8,000 | 5.5 K to 8 K (+45.45 %) |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | GOLDSTEIN JACK | Director | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | GOLDSTEIN JACK | Director | Option Exercise | A | 1.89 | 5,000 | 9,450 | 5,000 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | GOLDSTEIN JACK | Director | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | GOLDSTEIN JACK | Director | Buy | M | 0.00 | 5,000 | 0 | 12,500 | 7.5 K to 12.5 K (+66.67 %) |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | Clendeninn Neil James | Director | Option Exercise | A | 0.00 | 2,500 | 0 | 2,500 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | Clendeninn Neil James | Director | Option Exercise | A | 1.89 | 5,000 | 9,450 | 5,000 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | Clendeninn Neil James | Director | Option Exercise | M | 0.00 | 2,500 | 0 | 0 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | Clendeninn Neil James | Director | Buy | M | 0.00 | 2,500 | 0 | 14,562 | 12.1 K to 14.6 K (+20.73 %) |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | Smith David V | Director | Option Exercise | A | 0.00 | 2,500 | 0 | 2,500 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | Smith David V | Director | Option Exercise | A | 1.89 | 5,000 | 9,450 | 5,000 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | Smith David V | Director | Option Exercise | M | 0.00 | 2,500 | 0 | 0 | |
May 22 2015 | OGXI | ONCOGENEX PHARMACE ... | Smith David V | Director | Buy | M | 0.00 | 2,500 | 0 | 7,000 | 4.5 K to 7 K (+55.56 %) |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | A | 1.86 | 37,500 | 69,750 | 37,500 | |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | A | 0.00 | 18,750 | 0 | 18,750 | |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | M | 0.00 | 3,125 | 0 | 9,375 | |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | M | 0.00 | 2,500 | 0 | 5,000 | |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | M | 0.00 | 1,875 | 0 | 1,875 | |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Sell | S | 1.88 | 2,092 | 3,933 | 61,327 | 63.4 K to 61.3 K (-3.30 %) |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Buy | M | 0.00 | 7,500 | 0 | 63,419 | 55.9 K to 63.4 K (+13.41 %) |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | A | 0.00 | 37,500 | 0 | 37,500 | |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | A | 1.86 | 75,000 | 139,500 | 75,000 | |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | M | 0.00 | 6,250 | 0 | 18,750 | |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | M | 0.00 | 4,687 | 0 | 9,375 | |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | M | 0.00 | 4,687 | 0 | 4,687 | |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Sell | S | 1.88 | 7,543 | 14,181 | 107,138 | 114.7 K to 107.1 K (-6.58 %) |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Buy | M | 0.00 | 15,624 | 0 | 114,681 | 99.1 K to 114.7 K (+15.77 %) |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | Bencich John | CFO | Option Exercise | A | 1.86 | 25,000 | 46,500 | 25,000 | |
May 21 2015 | OGXI | ONCOGENEX PHARMACE ... | Bencich John | CFO | Option Exercise | A | 0.00 | 12,500 | 0 | 12,500 | |
Jan 30 2015 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | M | 0.00 | 20,100 | 0 | 0 | |
Jan 30 2015 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Payment of Exercise | F | 2.11 | 9,206 | 19,425 | 99,057 | 108.3 K to 99.1 K (-8.50 %) |
Jan 30 2015 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Buy | M | 0.00 | 20,100 | 0 | 108,263 | 88.2 K to 108.3 K (+22.80 %) |
Jan 30 2015 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | M | 0.00 | 13,400 | 0 | 0 | |
Jan 30 2015 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Payment of Exercise | F | 2.11 | 4,376 | 9,233 | 55,919 | 60.3 K to 55.9 K (-7.26 %) |
Jan 30 2015 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Buy | M | 0.00 | 13,400 | 0 | 60,295 | 46.9 K to 60.3 K (+28.57 %) |
Sep 19 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | M | 0.00 | 4,950 | 0 | 13,400 | |
Sep 19 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Payment of Exercise | F | 3.06 | 1,310 | 4,009 | 46,895 | 48.2 K to 46.9 K (-2.72 %) |
Sep 19 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Buy | M | 0.00 | 4,950 | 0 | 48,205 | 43.3 K to 48.2 K (+11.44 %) |
Aug 14 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | M | 0.00 | 20,000 | 0 | 0 | |
Aug 14 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Sell | S | 3.17 | 5,650 | 17,911 | 43,255 | 48.9 K to 43.3 K (-11.55 %) |
Aug 14 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Buy | M | 0.00 | 20,000 | 0 | 48,905 | 28.9 K to 48.9 K (+69.19 %) |
Sep 19 2014 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | M | 0.00 | 7,425 | 0 | 20,100 | |
Sep 19 2014 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Payment of Exercise | F | 3.06 | 3,401 | 10,407 | 88,163 | 91.6 K to 88.2 K (-3.71 %) |
Sep 19 2014 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Buy | M | 0.00 | 7,425 | 0 | 91,564 | 84.1 K to 91.6 K (+8.82 %) |
Aug 14 2014 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | M | 0.00 | 37,500 | 0 | 0 | |
Aug 14 2014 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Sell | S | 3.17 | 18,341 | 58,141 | 84,139 | 102.5 K to 84.1 K (-17.90 %) |
Aug 14 2014 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Buy | M | 0.00 | 37,500 | 0 | 102,480 | 65 K to 102.5 K (+57.71 %) |
Aug 12 2014 | OGXI | ONCOGENEX PHARMACE ... | Bencich John | CFO and PFO | Option Exercise | A | 0.00 | 20,000 | 0 | 20,000 | |
Aug 12 2014 | OGXI | ONCOGENEX PHARMACE ... | Bencich John | CFO and PFO | Option Exercise | A | 3.30 | 40,000 | 132,000 | 40,000 | |
Jun 16 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | A | 0.00 | 20,000 | 0 | 20,000 | |
Jun 16 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | A | 0.00 | 20,000 | 0 | 20,000 | |
Jun 16 2014 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | A | 0.00 | 37,500 | 0 | 37,500 | |
Jun 16 2014 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | A | 0.00 | 37,500 | 0 | 37,500 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | Smith David V | Director | Option Exercise | A | 0.00 | 2,500 | 0 | 2,500 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | Smith David V | Director | Option Exercise | A | 3.62 | 5,000 | 18,100 | 5,000 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | Smith David V | Director | Option Exercise | M | 0.00 | 2,500 | 0 | 0 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | Smith David V | Director | Buy | M | 0.00 | 2,500 | 0 | 4,500 | 2 K to 4.5 K (+125.00 %) |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | PARKER H STEWART | Director | Option Exercise | A | 0.00 | 2,500 | 0 | 2,500 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | PARKER H STEWART | Director | Option Exercise | A | 3.62 | 5,000 | 18,100 | 5,000 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | PARKER H STEWART | Director | Option Exercise | M | 0.00 | 2,500 | 0 | 0 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | PARKER H STEWART | Director | Buy | M | 0.00 | 2,500 | 0 | 7,500 | 5 K to 7.5 K (+50.00 %) |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | MATTINGLY MARTIN A | Director | Option Exercise | A | 0.00 | 2,500 | 0 | 2,500 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | MATTINGLY MARTIN A | Director | Option Exercise | A | 3.62 | 5,000 | 18,100 | 5,000 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | MATTINGLY MARTIN A | Director | Option Exercise | M | 0.00 | 2,500 | 0 | 0 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | MATTINGLY MARTIN A | Director | Buy | M | 0.00 | 2,500 | 0 | 5,500 | 3 K to 5.5 K (+83.33 %) |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | GOLDSTEIN JACK | Director | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | GOLDSTEIN JACK | Director | Option Exercise | A | 3.62 | 5,000 | 18,100 | 5,000 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | GOLDSTEIN JACK | Director | Option Exercise | M | 0.00 | 4,500 | 0 | 0 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | GOLDSTEIN JACK | Director | Buy | M | 0.00 | 4,500 | 0 | 7,500 | 3 K to 7.5 K (+150.00 %) |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | Clendeninn Neil James | Director | Option Exercise | A | 0.00 | 2,500 | 0 | 2,500 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | Clendeninn Neil James | Director | Option Exercise | A | 3.62 | 5,000 | 18,100 | 5,000 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | Clendeninn Neil James | Director | Option Exercise | M | 0.00 | 2,500 | 0 | 0 | |
Jun 09 2014 | OGXI | ONCOGENEX PHARMACE ... | Clendeninn Neil James | Director | Buy | M | 0.00 | 2,500 | 0 | 12,062 | 9.6 K to 12.1 K (+26.15 %) |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | Wyrick Susan D. | PAO | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | Wyrick Susan D. | PAO | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | Wyrick Susan D. | PAO | Option Exercise | A | 11.79 | 10,000 | 117,900 | 10,000 | |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | Wyrick Susan D. | PAO | Option Exercise | M | 0.00 | 516 | 0 | 1,547 | |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | Wyrick Susan D. | PAO | Sell | S | 12.25 | 182 | 2,230 | 1,312 | 1.5 K to 1.3 K (-12.18 %) |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | Wyrick Susan D. | PAO | Buy | M | 0.00 | 516 | 0 | 1,494 | 978 to 1.5 K (+52.76 %) |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | A | 0.00 | 25,000 | 0 | 25,000 | |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | A | 0.00 | 12,500 | 0 | 12,500 | |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | A | 11.79 | 25,000 | 294,750 | 25,000 | |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | M | 0.00 | 2,500 | 0 | 7,500 | |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Option Exercise | M | 0.00 | 1,875 | 0 | 3,750 | |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Sell | S | 12.25 | 1,250 | 15,313 | 28,905 | 30.2 K to 28.9 K (-4.15 %) |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | JACOBS CINDY | EVP, CMO | Buy | M | 0.00 | 4,375 | 0 | 30,155 | 25.8 K to 30.2 K (+16.97 %) |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | A | 0.00 | 40,000 | 0 | 40,000 | |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | A | 0.00 | 25,000 | 0 | 25,000 | |
Mar 18 2014 | OGXI | ONCOGENEX PHARMACE ... | Cormack Scott Daniel | President and CEO | Option Exercise | A | 11.79 | 50,000 | 589,500 | 50,000 |